
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Inc. has demonstrated a robust gene editing approach with sustained FVIII levels at 80% after 19 months in its non-human primate studies, indicating the potential long-term efficacy of its therapies. The company's proprietary metagenomics-derived genome editing toolbox, which includes various systems for both small and large gene edits, positions it well for advancements in genetic medicine. Furthermore, Metagenomi's focus on addressing significant diseases, such as Hemophilia A and cardiovascular disorders, underscores its commitment to developing innovative curative therapeutics that may drive future growth and market confidence.
Bears say
Metagenomi Inc. reported a substantial net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, indicating ongoing financial challenges. The company's stock is trading significantly below its cash position, which suggests potential upside; however, there are considerable risks that may impede future growth, including delays in advancing pipeline candidates, adverse clinical data outcomes, and potential long-term dilution. These factors contribute to a negative outlook, as the company faces significant hurdles in its pursuit of developing curative therapeutics and establishing a viable commercial presence.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares